MicroMedMark is a basic research, applied basic research, translational research and industrial transformation biomedical high-tech enterprise based on the scientific law that "extracellular microRNAs exist stably and have unique biological functions" originally discovered by the chief scientist Professor Chenyu Zhang.
Developer of immune-oncology drug research platform intended to find various treatment strategies and develop novel drugs for lung cancer therapy. The company focuses on immune cell based anticancer therapy using NK cells and T cell receptors, and clinical trials based on independent research infrastructure, enabling patients to receive new drugs for cancer and get cured.
ACT Therapeutics' ACT platform, is an advanced CAR-T technology that has a next-generation structure beyond the second-generation CAR-T cell therapy targeting existing blood cancer by overcoming the immune suppression microenvironment of solid cancer and activating surrounding immune cells. And various studies have secured animal experimental data on the efficacy and safety of the ACT platform, and confirmed the therapeutic characteristics while remaining in the immunosuppressive microenvironment of solid cancer and it complements the shortcomings of the existing second-generation CAR-T.
ProteoNic is a bioproduction technology company with strong commercial validation. The company licenses its technology platforms to clients performing development or manufacturing of biologics.The company benefits from being headquartered in Leiden, one of the largest life science hubs in Europe, and has an office in Boston for business development in the US.
AffyXell Therapeutics Co., Ltd. is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell & gene therapy to obstacle diseases that come from the imbalance of immune system homeostasis. AffyXell’s platform (also known as AFX) is created by converging the two proprietary technologies of its parent companies – Daewoong’s mesenchymal stem cell (MSC) and Avacta’s Affimer® platform. The immunomodulation function by MSC is further increased with the Affimer®, and the treatment developed by the AFX platform enhances restoring immunologic balance. AffyXell is developing pipelines taking this new therapeutic approach to lead in resolving fundamental causes of intractable diseases like immune rejection and autoimmune diseases.
AbTis is a patented biotechnology company specializing in antibody conjugation technology. Its pipeline aims to enhance the safety and efficacy of current antibody drug conjugation by applying AbTis conjugation technology to mAbs. Because it does not require genetic mutation or engineering to alter the antibody itself, its technology is applicable to natural antibodies under development, commercialized antibodies, or novel antibodies.Under the "patient first" philosophy, AbTis has been working hard to advance its ADC technology and co-develop product lines with other companies. AbTis' advanced ADC technology enables partners to co-develop pipelines in a truly open innovation environment.
The National Cancer Center of Japan was established in 1962 as the official cancer treatment and research center in Japan. Since its establishment, the National Cancer Center of Japan, as a core institution for clinical research and development of cancer treatments, has combined its own insights with those from the National Cancer Center Research Institute of Japan, the National Cancer Center Hospital of Japan (Tsukiji Branch), and the National Cancer Center East Hospital of Japan. The extensive experience of experts at Kashiwa Campus (Kashiwa Campus) has combined to conduct a series of cutting-edge research aimed at elucidating the pathophysiological mechanisms of cancer and developing cancer therapies based thereon.
OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor–specificity of the disease–related isoform, oxidized macrophage migration inhibitory factor (oxMIF). The Company is focused on developing multiple proprietary drug modalities to leverage oxMIF's potential as a target for systemic treatment of pancreatic, colorectal, ovarian and lung cancers, as well as for chronic inflammatory diseases. Equipped with a successful track–record in early–stage drug development, as well as a deep understanding of the target, OncoOne's leadership will advance a pipeline based on oxMIF's promise in oncology, with the goal of expanding into other disease areas.
Founded at the beginning of 2019, Abogen Biosciences is an innovative clinical-stage biomedical company committed to research and development of mRNA drugs. It has an industry-leading mRNA and nano-delivery technology platform with independent intellectual property rights. The company has built extensive product pipelines, ranging from infectious disease prevention and treatment to tumor immunity.
Suzhou Cure Med Biomedical Technology Co., Ltd. is located on the 2nd floor of C1 Building, Tengfei Science and Technology Park, Suzhou Industrial Park. It has a 3,000-square-meter laboratory that meets GMP standards, and a 10,000-square-meter production plant and R&D platform under construction. Cure Med focuses on the research and development of new-generation mRNA nucleic acid drugs. The circular mRNA technology platform and LNP nucleic acid delivery system have been built, and the pilot production of LNP nucleic acid drugs has been realized. The circular mRNA technology with independent intellectual property rights has filled the domestic gap. Cremed's R&D pipeline covers infectious disease vaccines, tumor immunity, protein replacement/gene therapy, cell therapy and other fields, and is actively promoting the IND application of circular mRNA drugs.
Suzhou Fangde Menda New Drug Development Co., Ltd. is a high-tech enterprise with breakthrough tumor immune cell drug research and development as its main development goal. It was founded by a team of senior returnees led by specially-appointed expert Dr. Li Jun. District registration and establishment, the company focuses on the breakthrough of the bottleneck of tumor immune cell therapy (ACT), focusing on the development and clinical treatment application of cell drugs on a global scale with the goal of first-in-efficacy and first-in-affordability.
Founded in 2012, AskGene operates at the intersection of science, technology and medicine. Our scientific team has developed several novel technologies, including our SmartKine® platform technology. These innovations enable us to overcome the limitations of current cytokine therapeutics, bringing next-generation therapies to patients with unmet medical needs.
SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity.
SunRock Biopharma transforms academic knowledge into therapeutic solutions through a disruptive open-innovation methodology. The core activity of the company lies in the development of innovative antibodies against highly invasive tumors with an urgent clinical need in oncology.
SunRock Biopharma strives to become a worldwide key agent in immunotherapy for oncology, through identification, development and transfer of academic knowledge to the pharmaceutical industry.
Beijing Neoletix Biological Technology (Neoletix) Co. Ltd.is a preclinical-stage biotech company committed to innovative research and development in hemostasis, thrombosis, rare diseases and therapies that can eradicate cancer tumors. At Neoletix, we have a long-standing interest and extensive expertise to go with it in the development of novel medicines to treat life-threatening diseases.
The company was initially formed to develop drugs that can treat a variety of coagulopathies, such as hereditary disorders (Hemophilia and VWD). With newly developed nanobody targeting platforms, the focus of the company has expanded into other pathological conditions including specific thrombotic diseases and cancers.
Neoletix has research sites both in China and U.S in order to have access to a broad range of technologies, people and other opportunities. Our mission is to develop novel therapies that will dramatically improve patient quality of life worldwide.
Initium Therapeutics is an innovative biotechnology company that discovers and develops first-in-class therapeutic antibody drugs against rare diseases such as hemophilia and fibrosis. Established in June of 2020, as a spin-off of Tiumbio, a biotechnology company in South Korea, in order to expand its capability to antibody drug development platforms, Initium Therapeutics has a strong scientific expertise in target identification/validation in fibrosis, immuno-oncology and hemophilia. Using its unique antibody development platforms of DNA immunization technology and AbCassette-High express system, Initium Therapeutics generates more diverse antigen-specific B cell repertoire and expedites screening of functional therapeutic antibodies, which mostly recognize very challenging small and complex conformational epitopes of membrane associated protein targets such as GPCRs (G protein coupled receptors), to treat unaddressed rare diseases.
The production base of Tongyao Group is located in the No. 1 Pharmaceutical Industrial Park of Datong City, covering an area of about 250,000 square meters and a total investment of nearly 1 billion yuan. The production sector has 11 production workshops and 33 automated production lines, all of which have passed the new version of GMP certification. It is an innovative pharmaceutical enterprise group integrating science, industry and trade.
The group has a number of invention patents and technology patents. It has three drug production enterprises, Shanxi Tongda Pharmaceutical Co., Ltd., Tongyao Group Datong Pharmaceutical Co., Ltd., Shanxi Weiqida Guangming Pharmaceutical Co., Ltd. and Shanxi Fuzhou Pharmaceutical Co., Ltd. Yuan Pharmaceutical Co., Ltd. is a pharmaceutical wholesale and retail enterprise. It is a large-scale pharmaceutical enterprise in Shanxi Province with a relatively complete variety of pharmaceutical production, many dosage forms.
3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the U.S.A. with business presence in Australia, China, Japan and the USA. It currently has four core businesses – cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.
Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences, and environmental science industries. It is focused on developing and commercializing innovative immune cell therapies and new drugs to address significant unmet medical needs for cancer patients in China and worldwide. Since inception in China in 2014, it has emerged into an international enterprise with a world-class management team that has the capability to become a leading global player in the biopharmaceutical sector. Through its collaboration with international research institutions, the company has embarked on a pipeline of new technologies in immune cell therapies and new cancer drug developments.
InnoBation Bio is a leading company that develops cancer biomarkers and immunotherapies. They are focusing on developments of cancer screening biomarkers for multiple types of cancers, antibody therapeutics including anti-CD47 antibody, and innovative CAR (chimeric antigen receptor) T cell therapies for hematologic and solid cancers. Mission of InnoBation Bio is to find track of human immune system, to develop innovative products on biomarkers and biotherapies, and to work through cancer disease with patients and clinicians.
Founded in 2001, Walvax is mainly engaged in research and development, manufacturing and distribution of safe and efficacious vaccines. With the purpose of “Help everyone live a healthy life”, Walvax aims to be a leader in public health, sustainably providing high-quality and innovative products to protect against the world’s deadliest diseases.
CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs. The group’s total assets are 50 billion RMB, with 27000 employees. Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI, and also the first pharmaceutical stock in the 50-year history of HSI. On March 22, 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group.
CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It was founded in 1969 and headquartered in Lianyungang, Jiangsu Province, China. With more than 14000 employees, CTTQ is the market leader in liver medicines in China. It is ranked 15th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2020, and among the top 5 most innovative Pharmaceutical Enterprises, and top 10 fastest-growing Pharmaceutical Manufacturers in China.
Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu Pharmaceutical has always committed itself to providing high-quality products to patients and the society. The company is the 1st Chinese company to obtain USFDA and EDQM approval for sterile APIs. Its finished formulations and APIs have been approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan and other national regulatory authorities.
EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000. Since then, EyeGene’s R&D Scientists have continued to research and develop innovative drugs for the treatment and prevention of age-related diseases.
Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand's business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand's business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand's OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand's Pelican® Expression Technology is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by more traditional systems. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International.
Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer. Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac) ; (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST) . The two platforms have been fully developed to the clinic-ready stage.
Stemirna Therapeutics was founded by a group of Chinese researchers and scholars in the Zhangjiang Drug Valley of Shanghai in 2016. Stemirna Therapeutics is dedicated to developing the best mRNA drug platforms and pipeline.
DMed is a global contract research organization (CRO) based in China. Many of DMed‘s employees are industry elites from transnational pharmaceutical enterprises and experts from medical products administrations in China and the US. With years of experience in drug development, DMed provides customers with valuable insights and reliable operation management in all areas from plan design to filing strategy, from operation execution to quality assurance, and offers high-quality and comprehensive clinical services to pharmaceutical companies.
Founded in 2015 and based in Seoul, South Korea, Eutilex Co., Ltd. (Stock Code: 263050.KOSDAQ) is a biotechnology company focused on the research and development of innovative T cell receptor (TCR) T cell, chimeric antigen receptor (CAR) T cell, and immunomodulatory antibody therapeutics for cancer and autoimmune diseases. Eutilex is developing preclinical and clinical-stage immunotherapeutics using its three in-house platform technologies.
Longyao biotechnology co,. was founded in 2013, committed to developing cell therapy technology, technology transformation, regulatory filing and submission. The company is a national high-tech enterprise, focusing on the R&D of immunotherapies, targeting at blood tumor, solid tumor, etc.
Merck is a leading global technology company focused on three major areas: 1) Medicine and health: providing prescription drugs for the treatment of cancer, multiple sclerosis and infertility, cardiovascular diseases and metabolic diseases; 2) Life sciences: provide innovative tools and laboratory supplies; 3) High-performance materials: organic light-emitting diodes, paints and cosmetic functional pigments, solar panel functional materials, etc.
Legend Biotech Co., Ltd. was established on November 17, 2014. Now, Legend has built end-to-end capabilities including one of the world’s largest internal discovery research engines in cell therapy and a global manufacturing network for robust and cost-effective product supply. With operations in the US, Europe and China, Legend is uniquely positioned to enable accelerated global clinical development and commercialization of innovative cell therapies.
Kang Litai Pharmaceutical Co., Ltd. was established in 2011. Since its establishment, it has been committed to the research and development of KLT-1101 in the field of comprehensive recovery of blood and tumor immunotherapy. KLT-1101 is a recombinant human protein cytokine, which has a positive response in the recovery of whole blood, inhibiting the growth of tumor cells and improving the immunity of patients.
REMD biotherapeutics is located in Camerillo, California, and Beijing, China (the "Corson Virtue"), dedicated to the development of innovative protein drugs to treat metabolic abnormalities and other serious diseases. The main product is REMD-477, which is a fully human antibody against glucagon, and is currently undergoing clinical trials for the treatment of diabetes. At the same time, a variety of therapeutic antibodies against G-protein coupled have been developed.
ABL Bio was established in South Korea in 2016 and plays a leading role in the development of therapeutic drugs for the treatment of immune cancer and degenerative brain diseases. Since its establishment, the company has successfully completed nearly 100 million US dollars of financing and is currently preparing for the public listing of the Korean Stock Exchange (KOSDAQ).
Selecxine was established in Pohang, South Korea in December 2018.Selecxine is a biological startup that uses platform technology to develop monoclonal antibodies. Based on the understanding of cancer immunology and protein structure information, Selecxine develops antibodies that bind to specific epitopes of targeted proteins to adjust and amplify the signals emitted by bifunctional biomolecules such as cytokines and cytokine receptors.
Genome & Company is a clinical stage biotechnology company headquartered in Korea, focusing on the discovery and development of a new wave of innovative immuno-oncology therapies through different models of microbiome, new targeted immune checkpoint inhibitors and fusion proteins to meet the unmet needs of cancer patients.
SAFE Pharmaceutical was established in 2016, based on national level drug research and development units such as the Institute of Drug Innovation of the Chinese Academy of Sciences and the former National Beijing Drug Safety Evaluation and Research Center, etc. SAFE pharmaceutical is committed to become a world-class one-stop medical CRO service company and has following units/divisions: pharmaceutical development consultation, formulation and pre-formulation development, efficacy, disease animal models, pharmacokinetics, toxicology and safety evaluation, bioanalysis, bio-equivalency, clinical phaseⅠ-III and pharmacovigilance, etc.
OmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic antibodies. All five types of OmniAb therapeutic human antibody platform, OmniRat, OmniFlic, OmniMouse, OmniChicken and OmniClic, use patented technology, have broad freedom to operate, produce highly diversified, fully human antibody repertoires optimized in vivo for immunogenicity, manufacturability, and therapeutic efficacy, and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability - Naturally Optimized Human Antibodies®.
CHONGQING CAMAB BIOTECH LTD is a High-Tech company，which has created the therapeutic antibody discovery platforms (CAMouseHG and CAMouseMG) with authentic human immunoglobulin loci including both human heavy and light chains and a nanobody discovery platform (CAMouseH) with human heavy chain-dCH1 locus; these platforms could generate high affinity, druggable, conventional human antibodies and nanobodies (heavy-chain only) upon antigen immunizations.